Merck (MRK) and Ridgeback Biotherapeutics' COVID pill Lagevrio (molnupiravir) did not meet the main goal of showing benefit in reducing hospitalizations and deaths in older adults.
Although the data suggests the vaccines are extremely effective and generally safe, analysis is still coming in about adverse events as well as effectiveness in specific patient populations.
On March 25, the U.S. government paused the distribution of GlaxoSmithKline (GSK) and Vir Biotechnology's (VIR) COVID-19 antibody therapy sotrovimab in certain states after the.